After multiple years of substantial losses, Delcath Systems recorded positive operating and net income in 2025, a pivotal inflection marked by commercial revenue from its niche liver cancer products. This profitability reflects improved manufacturing efficiency, supply chain stabilization, and expanding market acceptance of the HEPZATO KIT and CHEMOSAT system. Despite this progress, the company faces ongoing risks including dependency on limited suppliers, regulatory compliance burdens, and healthcare pricing pressures. Careful monitoring of reimbursement status, clinical adoption, and capital deployment will be key to sustaining growth momentum beyond this inaugural profit year.